Company H

H. Lundbeck A/S is a global biopharmaceutical company dedicated to the research, development, and commercialization of innovative treatments for brain diseases. Headquartered in Copenhagen, Denmark, the company focuses on psychiatric and neurological disorders, including depression, schizophrenia, migraine, and Alzheimer's disease. Lundbeck maintains a robust commercial portfolio featuring blockbuster products such as Trintellix, Rexulti, and Vyepti, while actively expanding its pipeline through strategic acquisitions like Longboard Pharmaceuticals. With a presence in over 100 countries and a history spanning more than 70 years in neuroscience, Lundbeck remains a leader in the central nervous system (CNS) therapeutic area. The company's R&D strategy emphasizes high-unmet-need indications and novel mechanisms of action to restore brain health.